Journal of the National Cancer Institute Advance Access originally published online on June 27, 2007
JNCI Journal of the National Cancer Institute 2007 99(13):996-997; doi:10.1093/jnci/djm055
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2007.
NEWS |
MDS Researchers Seek Treatments but Find Few
| The first 10% of the full text of this article appears below. |
Researchers have seen improvements in supportive care and the introduction of new therapies for myelodysplastic syndromes (MDSs), but the treatments remain largely supportive.
Currently available therapies benefit only a few patients with different stages of MDS, said Charles Schiffer, M.D., of the Karmanos Cancer Center at Wayne State University in Detroit. These clinical shortcomings reflect the inadequate understanding of the underlying biology of MDS. However, the development of tools for exploring the cellular and molecular biology of disease processes offers hope that a more effective therapy is possible.
Schiffer said that doctors now have tools to explain things they don't yet understand. "Now that you can do things with old slides or paraffin, don't throw these [resources] away," he said at the American Society of Hematology meeting in December. "Find someone who can help you explain things."
An abnormality of blood-forming cells in bone marrow, MDS has
Few Options Available
Studies Bring Hope